Rev Invest Clin
-
Review Historical Article
THE EVOLVING HISTORY OF THE REVISTA DE INVESTIGACIóN CLíNICA.
The Revista de Investigación Clínica (RIC) was established in 1948. It has been published continuously for 73 years. ⋯ The RIC, since 2015 known as RIC -Clinical and Translational Investigation-, is currently a nationally and internationally recognized scientific journal. This article briefly reviews the most outstanding historical features of the RIC since its foundation.
-
I was the Editor-in-Chief of the Revista de Investigación Clínica (RIC) from December 1999-May 2014. In this article, I present a review about how I initiated my experience in the RIC as an author, how I became the Editor-in-Chief, the philosophy of the RIC during my time, the type of publications we had and the citations these papers have received today, the special issues and consensus we published and how the RIC became the official publication of the Mexican Institutes of Health.
-
In the past three decades, several technologies designed for other purposes, have been applied in surgery to provide more precision to the surgical procedures and better outcomes. In surgery, innovation requires evidence before widespread implementation of novelties and a continuous quality improvement process to assess benefits and risks. ⋯ Innovation and technology should help to accomplish these conditions, but it must not be the center of surgical practice. We present here our perspective on the main issues related to technology and robotics focusing on evidence-based surgery.
-
Systemic autoimmune diseases are complex clinical conditions that arise in genetically predisposed individuals as a result of the interplay between their immune system and their environment. In this perspective, we briefly discuss our current understanding of the pathogenesis of autoimmunity and indicate four research avenues whose exploration will bring us closer to resolving fundamental questions that remain unanswered in this enigmatic field.
-
Transthyretin (TTR) amyloidosis (ATTR) is a progressive condition characterized by multiorgan accumulation of amyloid deposits composed of transthyretin (TTR) fibrils. Over the past decades, despite being a rare disease, ATTR amyloidosis has enabled top-tier therapeutics. In the 90s, organ transplantation was the mainstream therapeutic option and fostered distinct approaches, such as combined liver-heart transplant and domino (sequential) liver transplantation. ⋯ Over the past decade, oriented genetic therapies emerged to prevent, control, and, surprisingly, reverse amyloid deposition. Silencing the TTR gene using different strategies is flourishing, and ongoing trials continue to evaluate diverse approaches to optimize their application. The following perspective describes the currently available treatments for ATTR amyloidosis and the prospects on the potential application of these strategies in other medical fields.